Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions

Female Sexual Arousal DisorderFemale Sexual Dysfunction (FSD)

Interventions

DRUG

BZ371A

Formulation with the active ingredient

DRUG

Placebo

Formulation without the active ingredient

Trial Locations (1)

Ambulatório Jenny Farias do Hospital das Clínicas da UFMG, Belo Horizonte